Budd-Chiari syndrome medical therapy

	Budd-Chiari syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Budd-Chiari syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Budd-Chiari syndrome medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Budd-Chiari syndrome medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Budd-Chiari syndrome medical therapy
CDC on Budd-Chiari syndrome medical therapy
Budd-Chiari syndrome medical therapy in the news
Blogs on Budd-Chiari syndrome medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Budd-Chiari syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

The therapy for Budd-Chiari syndrome is aimed at alleviating the obstruction.Underlying conditions are aggressively treated.
Patients with Budd-Chiari syndrome are treated according to the severity of the disease.Treatment options include:
- Initial Medical therapy
- Endovascular procedure to restore vessel patency include
  - Angioplasty
  - Stenting
  - local thrombolysis
- Transjugular portosystemic shunt (TIPS)
- Liver transplantation

Medical therapy can be used for short-term symptomatic relief.However, the use of such medical therapy alone is associated with a high 2-year mortality rate.
A low-sodium diet is recommended for patients of Budd-Chiari syndrome. This helps in effective control of ascites.
Symptomatic treatment includes diuretics to control ascites, anticoagulants such as heparin and warfarin for hypercoagulable state.

Anticoagulation is recommended in all patients of BCS to prevent progression of the thrombosis.
Anticoagulation with LMWH should be initiated without delay soon after diagnosis.The risk of associated bleeding complications is comparable to patients with anticoagulation therapy for other indications.
Anticoagulation is maintained with a target value of Anti Xa between 0.5 and 0.8 IU/ml.
The goal is to maintain INR between 2.5 and 3 monitored by regular INR testing.
Prothrombin time and activated partial thromboplastin time are measured once anticoagulation is started and should be maintained within the therapeutic range.
Before switching from LMWH to oral anticoagulants, all contraindications has to be ruled out and a complete diagnostic workup has to be completed.

Thrombolytic agents include streptokinase, urokinase, recombinant tissue-type plasminogen activator (rt-PA).
Local thrombolysis performed by an interventional radiologist is preferable over systemic thrombolysis.
Systemic or intra-arterial thrombolysis in BCS has to be administered locally into the hepatic vein, inferior vena cava, and TIPS in case of acute thrombosis.